Inpharma Weekly

, Volume 788, Issue 1, pp 8–8 | Cite as

DAB 486-IL-2

the first genetically engineered fusion toxin to enter phase I trials as an anticancer agent
Newsletter Article

Keywords

Chronic Lymphocytic Leukaemia Lymphocytic Leukaemia Partial Remission Interferon Gamma Diphtheria 

Copyright information

© Adis International Ltd 1991

Personalised recommendations